STAT-activated macrophages, compositions, and uses thereof

JP2023547985A5Inactive Publication Date: 2024-11-07GEORGE WASHINGTON UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023516508
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-30
Filing Date
2021-10-29
Publication Date
2024-11-07
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current therapeutic strategies fail to effectively enhance antitumor immunity by reducing M2 macrophages or increasing M1 macrophages in the tumor microenvironment, leading to tumor growth and progression.

Method used

Reprogramming naive macrophages ex vivo using STAT inhibitors to activate them into an anti-tumor M1 phenotype, which can be administered to subjects to treat cancer and other diseases.

Benefits of technology

STAT-activated macrophages enhance antitumor immunity by increasing the ratio of M1 to M2 macrophages, thereby inhibiting tumor growth and progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022094319000001
    Figure 2022094319000001
  • Figure 2022094319000002
    Figure 2022094319000002
  • Figure 2022094319000003
    Figure 2022094319000003
Patent Text Reader

Abstract

The present disclosure provides signal transducer and activator of transcription (STAT)-activated macrophages, compositions comprising STAT-activated macrophages, methods for producing STAT-activated macrophages, and methods for treating diseases, such as cancer, by administering a therapeutically effective amount of STAT-activated macrophages. In one aspect, the present disclosure provides STAT-activated macrophages. In another aspect, the present disclosure provides compositions comprising STAT-activated macrophages. In another aspect, the present disclosure provides a method for producing STAT-activated macrophages, the method comprising isolating naive macrophages from a subject and treating the isolated naive macrophages ex vivo with a STAT inhibitor.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present disclosure provides signal transducer and activator of transcription (STAT)-activated macrophages, compositions comprising STAT-activated macrophages, methods for producing STAT-activated macrophages, and methods for treating diseases, such as cancer, by administering a therapeutically effective amount of STAT-activated macrophages or pharmaceutical compositions comprising STAT-activated macrophages. [Background technology]

[0002] Macrophages play a key role in the host's innate and adaptive immune responses. They help maintain and repair tissue homeostasis and fight infection. Macrophages exhibit functional heterogeneity based on their phenotype. They are classified as "M1" or "classically activated" macrophages and "M2" or "alternatively activated" macrophages. M2 macrophages are generally associated with tumors and secrete anti-inflammatory cytokines such as TGFβ and IL-10, which function by promoting tumor growth, angiogenesis, tumor invasion, and migration. In contrast, M1 macrophages secrete pro-inflammatory cytokines such as IL-12 and TNFα and have anti-tumor functions. M1 macrophages also actively scan the tumor microenvironment (TME) for tumor-associated antigens (TAAs) and present them to CD8 T cells to induce anti-tumor immunity. Therefore, the ratio of M1 / M2 macrophages in the TME plays an important role.

[0003] To enhance antitumor immunity, therapeutic strategies that either reduce M2 macrophages or increase M1 macrophages in the TME are needed. Summary of the Invention [Means for solving the problem]

[0004] Applicants have unexpectedly discovered that isolated macrophages can be reprogrammed ex vivo and polarized to an anti-tumor M1 phenotype by treatment with a STAT inhibitor. These STAT-activated macrophages can be administered to subjects to treat cancer and other diseases.

[0005] In one aspect, the present disclosure provides a STAT-activated macrophage.

[0006] In another aspect, the present disclosure provides a composition comprising a STAT-activated macrophage.

[0007] In another aspect, the present disclosure provides a method of producing STAT-activated macrophages, the method comprising isolating naive macrophages from a subject and treating the isolated naive macrophages ex vivo with a STAT inhibitor.

[0008] In another aspect, the present disclosure provides a method of treating a subject in need thereof, comprising administering a therapeutically effective amount of a STAT-activated macrophage or a composition comprising a STAT-activated macrophage to the subject, wherein the subject has cancer, pulmonary fibrosis, liver fibrosis, or cardiac fibrosis. [Brief explanation of the drawings]

[0009] [Figure 1] FIG. 11 is a graph showing the polarization efficiency of CD206 as a marker for M2 macrophages when M0 macrophages, M2 macrophages treated with vehicle, and M2 macrophages pretreated with nextulastat A (NA) or Stattic were analyzed by flow cytometry.

[0010] [Figure 2] 1 is a graph showing arginase I expression levels in macrophages pretreated with nextulastat A (NA) or Stattic.

[0011] [Figure 3] 1 is a graph showing TGFβ expression levels in macrophages pretreated with nextulastat A (NA) or Stattic.

[0012] [Figure 4] 1 is a graph showing FIZZ1 expression levels in macrophages pretreated with nextulastat A (NA) or Stattic. DETAILED DESCRIPTION OF THE INVENTION

[0013] I. Compositions of the Present Disclosure In one aspect, the present disclosure provides a STAT-activated macrophage.

[0014] In another aspect, the present disclosure provides a composition comprising a STAT-activated macrophage.

[0015] In another embodiment, the STAT-activated macrophages are produced from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor. In another embodiment, the subject is a mammal. In another embodiment, the subject is a human. In another embodiment, the naive macrophages are allogeneic macrophages, autologous macrophages, or a combination of allogeneic and autologous macrophages. In another embodiment, the naive macrophages are allogeneic macrophages. In another embodiment, the naive macrophages are autologous macrophages.

[0016] In another embodiment, STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated once ex vivo with a STAT inhibitor.

[0017] In another embodiment, the STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor two or more times.

[0018] In another embodiment, the STAT-activated macrophages are produced from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor for 72 hours or less, e.g., 48 hours or less, 36 hours or less, 24 hours or less, 12 hours or less, 8 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less.

[0019] In another embodiment, the STAT-activated macrophages are produced from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor and a macrophage polarization agent. In another embodiment, the macrophage polarization agent comprises lipopolysaccharide (LPS), interferon-γ, interleukin-4, or interleukin-13, or a combination thereof. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor before treatment with the macrophage polarization agent. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor after treatment with the macrophage polarization agent. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor and a macrophage polarization agent simultaneously. In another embodiment, the ex vivo treatment with the macrophage polarizing agent is for 72 hours or less, e.g., 48 hours or less, 36 hours or less, 24 hours or less, 12 hours or less, 8 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less.

[0020] In another embodiment, the STAT-activated macrophages are produced from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor and a tumor antigen. In another embodiment, the antigen comprises alphafetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), cancer antigen 15-3 (CA15-3), cancer antigen 19-9 (CA19-9), mucin 1 (MUC-1), epithelial tumor antigen (ETA), tyrosinase, or melanoma-associated antigen (MAGE), B melanoma antigen (BAGE), CAGE, New York esophageal squamous cell carcinoma 1 (NY-ESO-1), melanoma antigen recognized by T cells 1 (MART-1), prostate-specific antigen (PSA), human epidermal growth factor receptor 2 (HER2), calcitonin, p53, or a combination thereof. In another embodiment, the one or more tumor antigens comprise alphafetoprotein (AFP), carcinoembryonic antigen (CEA), CA-125, MUC-1, epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), or p53, or a combination thereof. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor before treatment with the tumor antigen. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor after treatment with the tumor antigen. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor and the tumor antigen simultaneously. In another embodiment, the ex vivo treatment with the tumor antigen is for 72 hours or less, e.g., 48 hours or less, 36 hours or less, 24 hours or less, 12 hours or less, 8 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less.

[0021] In another embodiment, STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor and a selective HDAC6 inhibitor. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor before treatment with a selective HDAC6 inhibitor. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor after treatment with a selective HDAC6 inhibitor. In another embodiment, the isolated naive macrophages are simultaneously treated with a STAT inhibitor and a selective HDAC6 inhibitor. In another embodiment, the ex vivo treatment with a selective HDAC6 inhibitor is for 72 hours or less, e.g., 48 hours or less, 36 hours or less, 24 hours or less, 12 hours or less, 8 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less.

[0022] In another embodiment, STAT-activated macrophages are produced from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor, a macrophage polarization agent, a tumor antigen, and a selective HDAC6 inhibitor. The naive macrophages can be treated ex vivo with a STAT inhibitor, a macrophage polarization agent, a tumor antigen, and a selective HDAC6 inhibitor simultaneously or individually in any order. For example, the naive macrophages can be treated ex vivo first with a STAT inhibitor, then a macrophage polarization agent, then a tumor antigen, and then a selective HDAC6 inhibitor; the naive macrophages can be treated ex vivo first with a macrophage polarization agent, then a STAT inhibitor, then a tumor antigen, and then a selective HDAC6 inhibitor; the naive macrophages can be treated ex vivo first with a STAT inhibitor, then a tumor antigen, then a macrophage polarization agent, and then a selective HDAC6 inhibitor; the naive macrophages can be treated ex vivo first with a selective HDAC6 inhibitor, then a STAT inhibitor, then a macrophage polarization agent, and then a tumor antigen. In another embodiment, the ex vivo treatment is with a STAT inhibitor, a macrophage polarization agent, a tumor antigen, and a selective HDAC6 inhibitor, for each agent independently for 72 hours or less, e.g., 48 hours or less, 36 hours or less, 24 hours or less, 12 hours or less, 8 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less.

[0023] The STAT-activated macrophages can be formulated as a pharmaceutical composition or medicament for clinical use and can include a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant. Thus, in one aspect, the present disclosure provides a composition comprising a STAT-activated macrophage and a pharmaceutically acceptable carrier, adjuvant, excipient, or diluent. Pharmaceutically acceptable carriers, diluents, excipients, or adjuvants are known in the art.

[0024] The compositions may be formulated for parenteral, systemic, intracavitary, intravenous, intraarterial, intramuscular, intrathecal, intraocular, intraconjunctival, intratumoral, subcutaneous, intradermal, intrathecal, oral or transdermal routes of administration, which may include injection or infusion.

[0025] Suitable formulations may include a sterile or isotonic medium, such as water for injection (WFI), containing STAT-activated macrophages. Medicaments and pharmaceutical compositions may be formulated in fluid forms, such as gels. Fluid formulations may be formulated for administration by injection or infusion (e.g., via a catheter) into a selected region of the human or animal body.

[0026] In one embodiment, the composition comprising STAT-activated macrophages is formulated for intratumoral or intravenous administration, e.g., macrophage-directed cancer immunotherapy. See, e.g., Mills et al., Cancer Research 76:513-516 (2016); Lee et al., J Control Release 240:527-540 (2016).

[0027] In accordance with the present disclosure, methods for producing pharmaceutically useful compositions are provided, which may include one or more steps selected from isolating / purifying STAT-activated macrophages produced according to the methods described herein and / or mixing STAT-activated macrophages produced according to a pharmaceutically acceptable carrier, adjuvant, excipient, or diluent.

[0028] For example, one aspect of the present disclosure relates to a method of formulating or manufacturing a medicament or pharmaceutical composition, the method comprising formulating the pharmaceutical composition or medicament by mixing STAT-activated macrophages produced according to the methods described herein with a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.

[0029] II. Methods for generating STAT-activated macrophages. In one aspect, the present disclosure provides a method of producing STAT-activated macrophages, the method comprising isolating naive macrophages from a subject and treating the isolated naive macrophages ex vivo with a STAT inhibitor. In another aspect, the subject is a mammal. In another aspect, the subject is a human. In another aspect, the naive macrophages are allogeneic macrophages, autologous macrophages, or a combination of allogeneic and autologous macrophages. In another aspect, the naive macrophages are allogeneic macrophages. In another aspect, the naive macrophages are autologous macrophages.

[0030] In another embodiment, STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated once ex vivo with a STAT inhibitor.

[0031] In another embodiment, the STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor two or more times.

[0032] In another embodiment, the STAT-activated macrophages are produced from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor for 72 hours or less, e.g., 48 hours or less, 36 hours or less, 24 hours or less, 12 hours or less, 8 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less.

[0033] In another embodiment, the selective STAT inhibitor is any one or more of the inhibitors provided in Table 1. [Table 1]

[0034] In another embodiment, the STAT inhibitor is a STAT1 inhibitor, a STAT2 inhibitor, a STAT3 inhibitor, a STAT4 inhibitor, a STAT5A inhibitor, a STAT5B inhibitor, or a STAT6 inhibitor.

[0035] In another embodiment, the STAT3 inhibitor is 6-nitrobenzo[b]thiophene-1,1-dioxide (Stattic).

[0036] In another embodiment, the STAT-activated macrophages are produced from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor and a macrophage polarization agent. In another embodiment, the macrophage polarization agent comprises lipopolysaccharide (LPS), interferon-γ, interleukin-4, or interleukin-13, or a combination thereof. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor before treatment with the macrophage polarization agent. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor after treatment with the macrophage polarization agent. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor and a macrophage polarization agent simultaneously. In another embodiment, the isolated naive macrophages are treated with a macrophage polarization agent for 72 hours or less, e.g., 48 hours or less, 36 hours or less, 24 hours or less, 12 hours or less, 8 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less.

[0037] In another embodiment, the STAT-activated macrophages are produced from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor and a tumor antigen. In another embodiment, the antigen comprises alphafetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), cancer antigen 15-3 (CA15-3), cancer antigen 19-9 (CA19-9), mucin 1 (MUC-1), epithelial tumor antigen (ETA), tyrosinase, or melanoma-associated antigen (MAGE), B melanoma antigen (BAGE), CAGE, New York esophageal squamous cell carcinoma 1 (NY-ESO-1), melanoma antigen recognized by T cells 1 (MART-1), prostate-specific antigen (PSA), human epidermal growth factor receptor 2 (HER2), calcitonin, p53, or a combination thereof. In another embodiment, the antigen comprises alphafetoprotein (AFP), carcinoembryonic antigen (CEA), CA-125, MUC-1, epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), or p53, or a combination thereof. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor before treatment with the tumor antigen. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor after treatment with the tumor antigen. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor and the tumor antigen simultaneously. In another embodiment, the isolated naive macrophages are treated with the tumor antigen for 72 hours or less, e.g., 48 hours or less, 36 hours or less, 24 hours or less, 12 hours or less, 8 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less.

[0038] In another embodiment, STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor and a selective HDAC6 inhibitor. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor before treatment with a selective HDAC6 inhibitor. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor after treatment with a selective HDAC6 inhibitor. In another embodiment, the isolated naive macrophages are treated with a STAT inhibitor and a selective HDAC6 inhibitor simultaneously. In another embodiment, the isolated naive macrophages are treated with a selective HDAC6 inhibitor for 72 hours or less, e.g., 48 hours or less, 36 hours or less, 24 hours or less, 12 hours or less, 8 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less.

[0039] In another embodiment, the selective HDAC6 inhibitor is a compound of Formula I or a pharmaceutically acceptable salt thereof. See above. In another embodiment, R 6a , R 6b , R 6c , R 6d , and R 6e are independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 In another embodiment, R is selected from the group consisting of haloalkyl. 6a , R 6b , R 6c , R 6d , and R 6e are each independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 In another embodiment, n is selected from the group consisting of alkoxy. In another embodiment, n is 1. In another embodiment, n is 2. In another embodiment, n can be 3.

[0040] In another embodiment, the selective HDAC6 inhibitor is a compound of Formula II or a pharmaceutically acceptable salt thereof. See above. In another embodiment, R 7a , R 7b , R 7c , R 7d , and R 7e are independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 In another embodiment, R is selected from the group consisting of haloalkyl. 7a , R 7b , R 7c , R 7d , and R 7e are each independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 In another embodiment, n is selected from the group consisting of alkoxy. In another embodiment, n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0041] In another embodiment, the selective HDAC6 inhibitor is a compound of Formula III or a pharmaceutically acceptable salt thereof. See above. In another embodiment, m is 0; [ka] is a double bond. In another embodiment, m is 1; [ka] is a single bond. In another embodiment, n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0042] In another embodiment, the selective HDAC6 inhibitor is a compound of formula IV or a pharmaceutically acceptable salt thereof. See above. In another embodiment, n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0043] In another embodiment, the selective HDAC6 inhibitor is a compound of Table 2 or a pharmaceutically acceptable salt thereof.

[0044] In another embodiment, the selective HDAC6 inhibitor is at least 20-fold more selective than one or more other HDAC isoforms, e.g., HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, HDAC10, or HDAC11.

[0045] In another embodiment, the selective HDAC6 inhibitor is at least 100-fold more selective than one or more other HDAC isoforms.

[0046] In another embodiment, the selective HDAC6 inhibitor is at least 600-fold more selective than one or more other HDAC isoforms.

[0047] III. Treating Diseases with Adoptive Transfer STAT-activated macrophages or pharmaceutical compositions comprising STAT-activated macrophages can be useful for adoptive cell therapy. Adoptive cell therapy involves the introduction of cells into a subject in need of treatment. In some cases, the cells are derived from the subject into which they are introduced (autologous cell therapy). See, for example, Moroni et al., Nature Medicine 25:1560-1565 (2019). That is, cells, such as macrophages, can be obtained from a patient, activated according to the methods described herein, and then returned to the same subject. The methods disclosed herein can also be used in allogeneic cell therapy, in which cells obtained from a different individual are introduced into a subject.

[0048] In one aspect, the present disclosure provides a method for treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of a STAT-activated macrophage or a composition comprising a STAT-activated macrophage to the subject. In another aspect, the disease or disorder is cancer, pulmonary fibrosis, liver fibrosis, or cardiac fibrosis.

[0049] In another aspect, the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising:

[0050] (a) isolating naive macrophages from a subject;

[0051] (b) treating naive macrophages ex vivo with STAT inhibitors to generate STAT-activated macrophages;

[0052] (c) administering STAT-activated macrophages to the subject.

[0053] In another aspect, the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising:

[0054] (a) isolating naive macrophages from a subject;

[0055] (b) treating naive macrophages ex vivo with STAT inhibitors to generate STAT-activated macrophages;

[0056] (c) treating STAT-activated macrophages with a macrophage polarizing agent;

[0057] (d) administering STAT-activated macrophages to the subject.

[0058] In another aspect, the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising:

[0059] (a) isolating naive macrophages from a subject;

[0060] (b) treating naive macrophages ex vivo with STAT inhibitors to generate STAT-activated macrophages;

[0061] (c) treating STAT-activated macrophages with tumor antigen;

[0062] (d) administering STAT-activated macrophages to the subject.

[0063] In another aspect, the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising:

[0064] (a) isolating naive macrophages from a subject;

[0065] (b) treating naive macrophages ex vivo with STAT inhibitors to generate STAT-activated macrophages;

[0066] (c) treating STAT-activated macrophages with a selective HDAC6 inhibitor;

[0067] (d) administering STAT-activated macrophages to the subject.

[0068] In another aspect, the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising:

[0069] (a) isolating naive macrophages from a subject;

[0070] (b) treating naive macrophages ex vivo with STAT inhibitors to generate STAT-activated macrophages;

[0071] (c) treating STAT-activated macrophages with a macrophage polarizing agent;

[0072] (d) treating STAT-activated macrophages with tumor antigen;

[0073] (e) administering STAT-activated macrophages to a subject.

[0074] In another aspect, the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising:

[0075] (a) isolating naive macrophages from a subject;

[0076] (b) treating naive macrophages ex vivo with STAT inhibitors to generate STAT-activated macrophages;

[0077] (c) treating STAT-activated macrophages with a macrophage polarizing agent;

[0078] (d) treating STAT-activated macrophages with a selective HDAC6 inhibitor;

[0079] (e) administering STAT-activated macrophages to a subject.

[0080] In another aspect, the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising:

[0081] (a) isolating naive macrophages from a subject;

[0082] (b) treating naive macrophages ex vivo with STAT inhibitors to generate STAT-activated macrophages;

[0083] (c) treating STAT-activated macrophages with tumor antigen;

[0084] (d) treating STAT-activated macrophages with a selective HDAC6 inhibitor;

[0085] (e) administering STAT-activated macrophages to a subject.

[0086] In another aspect, the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising:

[0087] (a) isolating naive macrophages from a subject;

[0088] (b) treating naive macrophages ex vivo with STAT inhibitors to generate STAT-activated macrophages;

[0089] (c) treating STAT-activated macrophages with a macrophage polarizing agent;

[0090] (d) treating STAT-activated macrophages with tumor antigen;

[0091] (e) treating STAT-activated macrophages with a selective HDAC6 inhibitor;

[0092] (f) administering STAT-activated macrophages to a subject.

[0093] In one embodiment, the subject from which the naive macrophages are isolated is the subject to which the STAT-activated macrophages were administered, i.e., the adoptive transfer is of autologous cells. In some embodiments, the subject from which the naive macrophages are isolated is a different subject from the subject to which the STAT-activated macrophages were administered, i.e., the adoptive transfer is of allogeneic cells.

[0094] In one aspect, a method of treating or preventing a disease or disorder in a subject comprises one or more of the following steps: isolating naive macrophages from a biological sample; treating the naive macrophages ex vivo with a STAT inhibitor; treating the treated macrophages with a macrophage polarization agent; treating the treated macrophages with a tumor antigen; treating the treated macrophages with a selective HDAC6 inhibitor; collecting the STAT-activated macrophages; mixing the STAT-activated macrophages with an adjuvant, diluent, or carrier; and administering the STAT-activated macrophages or a composition thereof to a subject.

[0095] In one embodiment, the disease or disorder to be treated / prevented is pulmonary fibrosis.

[0096] In another embodiment, the disease or disorder to be treated / prevented is liver fibrosis.

[0097] In another embodiment, the disease or disorder to be treated / prevented is cardiac fibrosis.

[0098] In another embodiment, the disease or disorder to be treated / prevented is cancer. STAT-activated macrophages and pharmaceutical compositions comprising STAT-activated macrophages can treat or prevent cancer, for example, inhibit cancer development / progression, delay / prevent the onset of cancer, reduce / delay / prevent tumor growth, reduce / delay / prevent metastasis, reduce the severity of cancer symptoms, reduce the number of cancer cells, reduce tumor size / volume, and / or prolong survival (e.g., progression-free survival).

[0099] In one embodiment, the cancer is a solid tumor. In another embodiment, the cancer is a hematological cancer. In another embodiment, the cancer is any one or more of the cancers in Table 3. [Table 2-1] [Table 2-2] [Table 2-3]

[0100] Exemplary hematological cancers include, but are not limited to, those listed in Table 4. In another embodiment, the hematological cancer is acute lymphocytic leukemia, chronic lymphocytic leukemia (such as B-cell chronic lymphocytic leukemia), or acute myeloid leukemia. [Table 3]

[0101] In one embodiment, the administration of the STAT-activated macrophages or compositions comprising STAT-activated macrophages is a "therapeutically effective" or "prophylactically effective" amount, which is sufficient to show benefit to the subject.

[0102] The actual amount administered, as well as the rate and time course of administration, will depend on the nature and severity of the disease or disorder. Prescribing treatment, including determining dosage, is within the responsibility of general practitioners and other physicians, and typically takes into account the disease / disorder to be treated, the condition of the individual subject, the site of delivery, the method of administration, and other factors known to practitioners. Examples of the above techniques and protocols can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.

[0103] Multiple doses of STAT-activated macrophages or pharmaceutical compositions comprising STAT-activated macrophages can be administered to a subject, and one or more, or each, of the doses can be accompanied by the simultaneous or sequential administration of another therapeutic agent.

[0104] Multiple doses can be separated by a predetermined time interval, which can be selected to be one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. By way of example, doses can be given once every 7, 14, 21, or 28 days (plus or minus 3, 2, or 1 day).

[0105] In another aspect, the present disclosure provides a method further comprising administering to the subject one or more of local radiation therapy, immune checkpoint blockade therapy, photothermal therapy, or chemotherapy.

[0106] HDAC6 inhibitors In one embodiment, STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT inhibitor and a selective HDAC6 inhibitor.

[0107] In another embodiment, the selective HDAC6 inhibitor is a compound of Formula I: [ka] or a pharmaceutically acceptable salt thereof (In the formula, R 6a , R 6b , R 6c , R 6d , and R 6e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-6 selected from the group consisting of cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, and optionally substituted 5- or 6-membered heterocyclo; R a and R b are independently hydrogen and C 1-4 alkyl; or R a and R b together with the nitrogen atom to which they are attached form a 3- to 10-membered heterocycle; R c is C 1-4 is alkyl; where n is 1, 2, or 3).

[0108] In another aspect, the disclosure provides a selective HDAC6 inhibitor, wherein the selective HDAC6 inhibitor is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R 6a , R 6b , R 6c , R 6d , and R 6e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 In another embodiment, R 6a , R 6b , R 6c , R 6d , and R 6e are each independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 alkoxy is selected from the group consisting of:

[0109] In another embodiment, the disclosure provides that the selective HDAC6 inhibitor is a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0110] In another embodiment, the selective HDAC6 inhibitor has Formula II: [ka] or a pharmaceutically acceptable salt thereof (In the formula, R 7a , R 7b , R 7c , R 7d , and R 7e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-6 selected from the group consisting of cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, and optionally substituted 5- or 6-membered heterocyclo; R a and R b are independently hydrogen and C 1-4 alkyl; or R a and R b together with the nitrogen atom to which they are attached form a 3- to 10-membered heterocycle; R c is C 1-4 is alkyl; where n is 1, 2, or 3).

[0111] In another aspect, the disclosure provides a selective HDAC6 inhibitor, wherein the selective HDAC6 inhibitor is a compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein R 7a , R 7b , R 7c , R 7d , and R 7e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 In another embodiment, R 7a , R 7b , R 7c , R 7d , and R 7e are each independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 alkoxy is selected from the group consisting of:

[0112] In another embodiment, the selective HDAC6 inhibitor is a compound of Formula II or a pharmaceutically acceptable salt thereof, wherein n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0113] In another embodiment, the selective HDAC6 inhibitor has Formula III: [ka] or a pharmaceutically acceptable salt thereof (In the formula, R 4a and R 4b are independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 selected from the group consisting of alkoxy; R 4c and R 4d is independently selected from the group consisting of hydrogen and methyl; m is 0 or 1; n is 1, 2, or 3; [ka] represents a single or double bond).

[0114] In another embodiment, the selective HDAC6 inhibitor is a compound of Formula III, or a pharmaceutically acceptable salt thereof, wherein m is 0; [ka] can represent a double bond).

[0115] In another embodiment, the selective HDAC6 inhibitor is a compound of Formula III or a pharmaceutically acceptable salt thereof, wherein m is 1; [ka] is a single bond).

[0116] In another embodiment, the selective HDAC6 inhibitor is a compound of Formula III or a pharmaceutically acceptable salt thereof, wherein n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0117] In another embodiment, the selective HDAC6 inhibitor has Formula IV: [ka] or a pharmaceutically acceptable salt thereof (In the formula, R 5a and R 5c are independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 selected from the group consisting of alkoxy; where n is 1, 2, or 3).

[0118] In another embodiment, the selective HDAC6 inhibitor is a compound of Formula IV or a pharmaceutically acceptable salt thereof, wherein n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0119] In another embodiment, the selective HDAC6 inhibitor is a compound of Table 2 (see below) or a pharmaceutically acceptable salt thereof.

[0120] In another embodiment, the selective HDAC6 inhibitor is at least 20-fold more selective than one or more other HDAC isoforms, e.g., HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, HDAC10, or HDAC11.

[0121] In another embodiment, the selective HDAC6 inhibitor is at least 100-fold more selective than one or more other HDAC isoforms.

[0122] In another embodiment, the selective HDAC6 inhibitor is at least 600-fold more selective than one or more other HDAC isoforms.

[0123] Radiation therapy In one aspect, the methods provided herein include administering STAT-activated macrophages or a composition comprising STAT-activated macrophages to a subject in combination with radiation therapy. The methods provided herein are not limited by the type, amount, or delivery and administration system used to deliver a therapeutic dose of radiation to a subject. For example, the subject can receive photon radiation therapy, particle beam radiation therapy, other types of radiation therapy, and combinations thereof. In some aspects, radiation is delivered to a subject using a linear accelerator. In yet another aspect, radiation is delivered using a gamma knife.

[0124] The radiation source can be external or internal to the subject. External radiation therapy is the most common and involves directing a beam of high-energy radiation through the skin to the tumor site, using, for example, a linear accelerator. The radiation beam is localized to the tumor site, but exposure to normal, healthy tissue is nearly impossible to avoid. However, external radiation is usually well tolerated by the subject. Internal radiation therapy involves implanting a radioactive source, such as beads, wires, pellets, capsules, and particles, within the body at or near the tumor site, and includes the use of a delivery system that specifically targets cancer cells (e.g., using particles bound to cancer cell-binding ligands). Such implants can be removed after treatment or left inactive in the body. Types of internal radiation therapy include, but are not limited to, brachytherapy, interstitial radiation, intracavitary radiation, and radioimmunotherapy.

[0125] The subject may optionally be treated with a radiosensitizer (e.g., metronidazole, misonidazole, intra-arterial Budr, intravenous iododeoxyuridine (IudR), nitroimidazole, 5-substituted-4-nitroimidazole, 2H-isoindoledione, [[(2-bromoethyl)-amino]methyl]-nitro-1H-imidazole-1-ethanol, nitroaniline derivatives, DNA-affinity hypoxia-selective cytotoxins, halogenated DNA ligands, 1,2,4 benzotriazine oxide, 2-nitroimidazole derivatives, fluorine-containing nitroazole derivatives, benzamides, nicotinamide, acridine-intercalators, 5-thio These drugs may be administered with drugs such as tretrazol derivatives, 3-nitro-1,2,4-triazole, 4,5-dinitroimidazole derivatives, hydroxylated texafrin, cisplatin, mitomycin, tiripazamine, nitrosoureas, mercaptopurine, methotrexate, fluorouracil, bleomycin, vincristine, carboplatin, epirubicin, doxorubicin, cyclophosphamide, vindesine, etoposide, paclitaxel, fever (hyperthermia), and radioprotectors (e.g., cysteamine, aminoalkyl dihydrogen phosphorothioates, amifostine (WR2721), IL-1, IL-6, etc.). Radiosensitizers increase tumor cell death. Radioprotectors protect healthy tissue from the harmful effects of radiation.

[0126] Any type of radiation can be administered to a subject, as long as the radiation dose is tolerable by the subject without unacceptable negative side effects.Suitable types of radiation therapy include, for example, ionizing (electromagnetic) radiation therapy (e.g., X-rays or gamma rays) or particle beam radiation therapy (e.g., high linear energy radiation).Ionizing radiation is defined as radiation that contains particles or photons with sufficient energy to cause ionization, i.e., the gain or loss of electrons (e.g., as described in US5,770,581, which is incorporated herein by reference in its entirety).The effect of radiation can be at least partially controlled by clinicians.In one embodiment, the radiation dose is fractionated to maximize exposure to target cells and reduce toxicity.

[0127] In one embodiment, the total dose of radiation administered to a subject is from about 0.01 Gray (Gy) to about 100 Gy. In another embodiment, from about 10 Gy to about 65 Gy (e.g., about 15 Gy, 20 Gy, 25 Gy, 30 Gy, 35 Gy, 40 Gy, 45 Gy, 50 Gy, 55 Gy, or 60 Gy) is administered over the course of treatment. In some embodiments, the total dose of radiation can be administered over a single day, but ideally, the total dose is divided and administered over several days. Desirably, radiation therapy is administered over at least about 3 days, e.g., at least 3, 4, 5, 7, 10, 14, 17, 21, 25, 28, 32, 35, 38, 42, 46, 52, or 56 days (about 1 to 8 weeks). Thus, a daily dose of radiation may range from about 1 to 5 Gy (e.g., about 1 Gy, 1.5 Gy, 1.8 Gy, 2 Gy, 2.5 Gy, 2.8 Gy, 3 Gy, 3.2 Gy, 3.5 Gy, 3.8 Gy, 4 Gy, 4.2 Gy, or 4.5 Gy), or from 1 to 2 Gy (e.g., 1.5 to 2 Gy). The daily dose of radiation should be sufficient to induce destruction of the target cells. When extended over a period of time, in one embodiment, radiation is not administered every day, thereby allowing the animal to rest and realize the effects of the treatment. For example, in one embodiment, radiation is administered for five consecutive days during each week of treatment, with no radiation administered for two days, thereby allowing for two days of rest per week. However, in other embodiments, radiation is administered one day per week, two days per week, three days per week, four days per week, five days per week, six days per week, or all seven days per week, depending on the mammal's response and any potential side effects. Radiation therapy can begin at any time during the treatment period. In one embodiment, radiation is administered beginning in week 1 or week 2 and continuing for the remainder of the treatment period. For example, radiation is administered from week 1 to week 6 or week 2 to week 6 of a six-week treatment period, e.g., for treating solid tumors. Alternatively, radiation is administered from week 1 to week 5 or week 2 to week 5 of a five-week treatment period. However, these exemplary radiation therapy administration schedules are not intended to limit the methods provided herein.

[0128] Immune checkpoint blockade therapy In one aspect, the methods provided herein include administering STAT-activated macrophages or a composition comprising STAT-activated macrophages to a subject in combination with immune checkpoint blockade therapy. Immune checkpoint inhibitors are therapeutics that block immune system inhibitor checkpoints. Immune checkpoints can be stimulatory or inhibitory. Blockade of inhibitory immune checkpoints activates immune system function and is useful for cancer immunotherapy. Pardoll, Nature Reviews, Cancer 12:252-64 (2012). Tumor cells turn off activated T cells when they bind to specific T cell receptors. Immune checkpoint inhibitors prevent tumor cells from binding to T cells, resulting in the T cells remaining activated. In fact, the coordinated action of cellular and soluble components combats pathogens and cancer damage. Modulation of an immune system pathway can involve altering the expression or functional activity of at least one component of the pathway to modulate the immune system response. US2015 / 0250853. Examples of immune checkpoint inhibitors include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG3 inhibitors, TIM3 inhibitors, CD47 inhibitors, and B7-H1 inhibitors. Thus, in one aspect, the immune checkpoint inhibitor is selected from the group consisting of PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG3 inhibitors, TIM3 inhibitors, and CD47 inhibitors.

[0129] In another embodiment, the immune checkpoint inhibitor is a programmed cell death protein (PD-1) inhibitor. PD-1 is a T cell co-inhibitory receptor that plays a crucial role in the ability of tumor cells to evade the host's immune system. Blocking the interaction between PD-1 and its ligand, PD-L1, enhances immune function and mediates anti-tumor activity. Examples of PD-1 inhibitors include antibodies that specifically bind to PD-1. Specific anti-PD-1 antibodies include, but are not limited to, nivolumab, pembrolizumab, STI-A1014, and pidiluzumab. For a general discussion of the availability, production methods, mechanism of action, and clinical studies of anti-PD-1 antibodies, see US2013 / 0309250, US6,808,710, US7,595,048, US8,008,449, US8,728,474, US8,779,105, US8,952,136, US8,900,587, US9,073,994, US9,084,776, and Naido et al., British Journal of Cancer 111:2214-19 (2014).

[0130] In another aspect, the immune checkpoint inhibitor is a PD-L1 (also known as B7-H1 or CD274) inhibitor. Examples of PD-L1 inhibitors include antibodies that specifically bind to PD-L1. Specific anti-PD-L1 antibodies include, but are not limited to, avelumab, atezolizumab, durvalumab, and BMS-936559. For a general discussion of availability, methods of production, mechanism of action, and clinical studies, see US8, 217, 149, US2014 / 0341917, US2013 / 0071403, WO2015036499, and Naido et al., British Journal of Cancer 111:2214-19 (2014).

[0131] In another embodiment, the immune checkpoint inhibitor is a CTLA-4 inhibitor. CTLA-4, also known as cytotoxic T-lymphocyte antigen 4, is a protein receptor that downregulates the immune system. CTLA-4 is characterized as a "brake" that binds to costimulatory molecules on antigen-presenting cells, preventing their interaction with CD28 on T cells and generating a pronounced inhibitory signal that suppresses T cell activation. Examples of CTLA-4 inhibitors include antibodies that specifically bind to CTLA-4. Specific anti-CTLA-4 antibodies include, but are not limited to, ipilimumab and tremelimumab. For a general discussion of availability, production methods, mechanism of action, and clinical studies, see US Pat. No. 6,984,720, US Pat. No. 6,207,156, and Naido et al., British Journal of Cancer 111:2214-19 (2014).

[0132] In another aspect, the immune checkpoint inhibitor is a LAG3 inhibitor. LAG3, lymphocyte activation gene 3, is a negative costimulatory receptor that regulates T cell homeostasis, proliferation, and activation. Furthermore, LAG3 has been reported to be involved in the suppressive function of regulatory T cells (Tregs). Most LAG3 molecules are retained in cells near microtubule-organizing centers and are induced only after antigen-specific T cell activation. (US2014 / 0286935) Examples of LAG3 inhibitors include antibodies that specifically bind to LAG3. Specific anti-LAG3 antibodies include, but are not limited to, GSK2831781. For a general discussion of availability, production methods, mechanism of action, and clinical studies, see US2011 / 0150892, US2014 / 0093511, US20150259420, and Huang et al., Immunity 21:503-13 (2004).

[0133] In another embodiment, the immune checkpoint inhibitor is a TIM3 inhibitor. TIM3, T cell immunoglobulin and mucin domain 3, is a T H 1 and T CThe TIM3 pathway is an immune checkpoint receptor that functions to limit the duration and magnitude of T cell responses. The TIM3 pathway mediates dysfunctional CD8+ / CD8+ T cells, two reported immune cell populations that constitute immunosuppression in tumor tissue. + Because it is expressed on T cells and Tregs, it is considered a target for anti-cancer immunotherapy. Anderson, Cancer Immunology Research 2:393-98 (2014). Examples of TIM3 inhibitors include antibodies that specifically bind to TIM3. For a general discussion of availability, manufacturing methods, mechanism of action, and research on TIM3 inhibitors, see US20150225457, US20130022623, US8,522,156, Ngiow et al., Cancer Res 71:6567-71 (2011), Ngiow, et al., Cancer Res 71:3540-51 (2011), and Anderson, Cancer Immunology Res 2:393-98 (2014).

[0134] In another embodiment, the immune checkpoint inhibitor is a CD47 inhibitor. See Unanue, ER, PNAS 110:10886-87 (2013).

[0135] The term "antibody" is specifically meant to include intact monoclonal antibodies, polyclonal antibodies, and multispecific antibodies formed from at least two intact antibodies, so long as they exhibit the desired biological activity. In one embodiment, the antibody is a humanized monoclonal antibody produced by recombinant genetic engineering.

[0136] Another class of immune checkpoint inhibitors includes polypeptides that bind to and block the PD-1 receptor on T cells without inducing inhibitor signaling. Such peptides include B7-DC, B7-H1, B7-1, and B7-2 polypeptides, and soluble fragments thereof, as disclosed in U.S. Patent No. 8,114,845.

[0137] Another class of immune checkpoint inhibitors includes compounds with a peptide moiety that inhibits PD-1 signaling. Examples of such compounds are disclosed in U.S. Patent No. 8,907,053.

[0138] Another class of immune checkpoint inhibitors includes inhibitors of specific metabolic enzymes, such as indoleamine 2,3 dioxygenase (IDO), which is expressed by infiltrating myeloid and tumor cells. The IDO enzyme inhibits immune responses by depleting T cells of amino acids required for anabolic function or by synthesizing specific natural ligands for cytosolic receptors that can alter lymphocyte function. Pardoll, Nature Reviews. Cancer 12:252-64 (2012); Lob, Cancer Immunol Immunother 58:153-57 (2009). Specific IDO blockers include, but are not limited to, levo-1-methyltryptophan (L-1MT) and 1-methyl-tryptophan (1MT). Qian et al., Cancer Res 69:5498-504 (2009); and Lob et al., Cancer Immunol Immunother 58:153-7 (2009).

[0139] In one embodiment, the immune checkpoint inhibitor is nivolumab, pembrolizumab, pidilizumab, STI-A1110, avelumab, atezolizumab, durvalumab, STI-A1014, ipilimumab, tremelimumab, GSK2831781, BMS-936559, or MED14736.

[0140] chemotherapy In one embodiment, the methods provided herein include administering to a subject a composition comprising a STAT-activated macrophage or a composition comprising a STAT-activated macrophage in combination with chemotherapy. In one embodiment, the chemotherapy includes one of the anticancer drugs or combinations of anticancer drugs listed in Table 5. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6] [Table 4-7] [Table 4-8] [Table 4-9] [Table 4-10]

[0141] Photothermal therapy In one aspect, the methods provided herein include administering STAT-activated macrophages or a composition comprising STAT-activated macrophages to a subject in combination with photothermal therapy. Photothermal therapy refers to the use of electromagnetic radiation (most often infrared wavelengths) to treat various medical conditions, including cancer. This approach is an extension of photodynamic therapy, in which a photosensitizer is excited with a specific band of light. This activation causes the sensitizer to enter an excited state, releasing vibrational energy (heat) and killing the target cell. Unlike photodynamic therapy, photothermal therapy does not require oxygen to interact with the target cell or tissue. Current research also indicates that photothermal therapy can use lower-energy, longer-wavelength light, which is therefore less harmful to other cells and tissues.

[0142] Most materials currently being investigated for photothermal therapy are nanoscale. One of the main reasons behind this is the enhanced permeability and retention observed with particles in a specific size range (typically 20-300 nm). (Maeda et al., Journal of Controlled Release, 65(1-2), 271-284 (2000)). Molecules within this range have been observed to preferentially accumulate in tumor tissue. When tumors form, new blood vessels are required to support their growth. These new blood vessels within and near tumors have different properties than normal blood vessels, such as poor lymphatic drainage and a disorganized, leaky vasculature. These factors result in significantly higher concentrations of specific particles within tumors compared to other parts of the body. Combining this phenomenon with active targeting modalities (e.g., antibodies) has recently been investigated by researchers.

[0143] IV. Definition The term "STAT-activated macrophages" refers to naive macrophages treated with a STAT inhibitor ex vivo. In another embodiment, the STAT-activated macrophages are first treated with a STAT inhibitor ex vivo, and then treated with a macrophage polarization agent and / or a tumor antigen and / or a selective HDAC6 inhibitor ex vivo. In another embodiment, the STAT-activated macrophages are treated with a macrophage polarization agent and / or a tumor antigen and / or a selective HDAC6 inhibitor ex vivo, and then treated with a STAT inhibitor ex vivo.

[0144] The STAT protein family consists of seven members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6.

[0145] In one embodiment, the STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT1 inhibitor.

[0146] In another embodiment, the STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT2 inhibitor.

[0147] In another embodiment, the STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT3 inhibitor.

[0148] In another embodiment, the STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT4 inhibitor.

[0149] In another embodiment, the STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT5A inhibitor.

[0150] In another embodiment, the STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT5B inhibitor.

[0151] In another embodiment, the STAT-activated macrophages are generated from naive macrophages isolated from a subject and treated ex vivo with a STAT6 inhibitor.

[0152] As used herein, the terms "selective HDAC6 inhibitor," "HDAC6-selective inhibitor," and the like refer to a compound that preferentially inhibits histone deacetylase 6 over one or more other histone deacetylase isoforms, e.g., HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, HDAC10, and / or HDAC11, in a cell-based in vitro assay. For example, HDAC6 IC 50 = 5 nM, and HDAC1 IC 50Compounds with an HDAC6 IC of 500 nM are selective HDAC6 inhibitors that are 100-fold more selective than HDAC1; 50 = 5nM, HDAC1 IC 50 = 500 nM, and HDAC3 IC 50 = 50 nM is a selective HDAC6 inhibitor that is 100-fold more selective than HDAC1 and 10-fold more selective than HDAC3. In one aspect, a selective HDAC6 inhibitor preferentially inhibits HDAC6 over HDAC1. In another aspect, a selective HDAC6 inhibitor preferentially inhibits HDAC6 over HDAC1 and one or more other HDAC isoforms.

[0153] In one embodiment, the selective HDAC6 inhibitor is at least about 5-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 10-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 15-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 20-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 30-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 40-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 50-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 100-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 150-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 200-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 250-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 500-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 750-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 1000-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 2000-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 3000-fold selective over one or more other HDAC isoforms. HDAC6 selectivity over other HDAC isoforms in cell-based assays can be determined using methods known in the art.

[0154] In another embodiment, the selective HDAC6 inhibitor is at least about 10- to 3000-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 20- to 3000-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 50- to 3000-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 100- to 3000-fold selective over one or more other HDAC isoforms. In another embodiment, the selective HDAC6 inhibitor is at least about 500- to 3000-fold selective over one or more other HDAC isoforms.

[0155] In one embodiment, HDAC6 selectivity is determined using human recombinant full-length HDACs isolated from a baculovirus expression system in Sf9 cells. Depending on the HDAC isoform being tested, e.g., derived from residues 379-382 of p53, an acetylated fluorogenic peptide is used as the substrate. See http: / / www.reactionbiology.com / webapps / site / HDACAssay.aspx?page=HDACs&id=-%203. The reaction buffer consists of 50 mM Tris-HCl pH 8.0, 127 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 mg / mL BSA, and a final concentration of 1% DMSO. The test compound is delivered to the enzyme mixture in DMSO. After a 5-10 minute preincubation, the substrate is added and the mixture is incubated at 30°C for 2 hours. Trichostatin A and a developer are added to quench the reaction and generate fluorescence, respectively. Dose-response curves were generated and IC values ​​were calculated from the resulting plots. 50 Determine the value. See Bergman et al., J Med Chem. 55:9891-9899 (2012). Selective HDAC6 inhibitors are meant to include the parent compound and any pharmaceutically acceptable salts or solvates thereof.

[0156] In one embodiment, the selective HDAC6 inhibitor is a compound disclosed in Shen and Kozikowski, Expert Opinion on Therapeutic Patents 30:121-136 (2020).

[0157] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in Bergman et al., J Med Chem. 55:9891-9899 (2012).

[0158] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2014072714.

[0159] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2016067040.

[0160] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2016190630.

[0161] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2019139921.

[0162] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in US20150239869.

[0163] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2015054474.

[0164] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017075192.

[0165] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2018089651.

[0166] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2014181137.

[0167] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2016067038.

[0168] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017208032.

[0169] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2016168598.

[0170] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2016168660.

[0171] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017218950.

[0172] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in US20160221973.

[0173] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in US20160222022.

[0174] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in US20160221997.

[0175] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2014178606.

[0176] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2015087151.

[0177] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2015102426.

[0178] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2015137750.

[0179] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2018189340.

[0180] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2018130155.

[0181] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017222950.

[0182] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017222951.

[0183] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017222952.

[0184] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2016031815.

[0185] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017014170.

[0186] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017014321.

[0187] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017033946.

[0188] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2019027054.

[0189] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2019166824.

[0190] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2019110663.

[0191] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017018803.

[0192] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017018805.

[0193] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017023133.

[0194] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2017065473.

[0195] In another embodiment, the selective HDAC6 inhibitor is a compound disclosed in WO2018183701.

[0196] In another embodiment, the selective HDAC6 inhibitor is a compound having Formula V: [ka] (In the formula, X is selected from the group consisting of: [ka] R 1 is hydrogen and C 1-4 selected from the group consisting of alkyl; R 2 is an optionally substituted C-C 14 selected from the group consisting of aryl and aralkyl; R 3 is an optionally substituted C-C 14 Aryl, and optionally substituted 5- to 14-membered heteroaryl and —C(═O)NRd R e selected from the group consisting of: R 4a , R 4b , R 4e , and R 4f are independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 selected from the group consisting of haloalkyl, and haloalkoxy; R 4c and R 4d are independently hydrogen and C 1-4 selected from the group consisting of alkyl; R 4c and R 4d together with the carbon atom to which they are attached to form -C(=O)-; R 5a , R 5b , R 5c , and R 5d are independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 selected from the group consisting of haloalkyl, and haloalkoxy; Z is -O-, -N(R 8 )—, and —C(═O)—; or Z is absent; R 8 is hydrogen, C 1-4 Alkyl, optionally substituted C 3-6Cycloalkyl, optionally substituted C-C 14 selected from the group consisting of aryl, aralkyl, optionally substituted 5- to 14-membered heteroaryl, and heteroaralkyl; m is 0, 1, or 2; n is 1, 2, 3, 4, 5, or 6; [ka] represents a single or double bond; R a , R b , R d , and R e are independently hydrogen, C 1-6 Alkyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C-C 14 aryl, optionally substituted 5- to 14-membered heteroaryl; R a and R b together with the nitrogen atom to which they are attached form a 3- to 12-membered optionally substituted heterocycle; R d and R e together with the nitrogen atom to which they are attached form a 3- to 12-membered optionally substituted heterocycle; R c is C 1-4 alkyl).

[0197] In another aspect, the selective HDAC6 inhibitor is a compound having formula V, and pharmaceutically acceptable salts and solvates thereof, with the proviso that when Z is absent, R 3 is a bicyclic or tricyclic C 10-14 Aryl, bicyclic or tricyclic 9- to 14-membered heteroaryl, or —C(═O)NR d R e is.

[0198] In another aspect, the selective HDAC6 inhibitor is a compound having formula V, and pharmaceutically acceptable salts and solvates thereof, wherein X is X-1, X-2, X-3, or X-4; Z is -O-; R 1 is hydrogen and C 1-4 selected from the group consisting of alkyl; R 2 is an optionally substituted C-C 14 is aryl; R 3 is an optionally substituted C-C 14 aryl, and optionally substituted 5- to 14-membered heteroaryl; R 4a and R 4b are independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 selected from the group consisting of haloalkyl, and haloalkoxy; R 4c and R 4d are independently hydrogen and C 1-4 selected from the group consisting of alkyl; R 5a , R 5b , R 5c , and R 5d are independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6selected from the group consisting of haloalkyl, and haloalkoxy; R a and R b are independently hydrogen and C 1-6 selected from the group consisting of alkyl; R a and R b together with the nitrogen atom to which they are attached form a 3- to 7-membered optionally substituted heterocycle; R c is C 1-4 alkyl).

[0199] In another embodiment, the selective HDAC6 inhibitor is a compound having formula V, where X is X-1. 1 is hydrogen. In another embodiment, R 2 is optionally substituted phenyl. In another embodiment, R 2 is optionally substituted 1-naphthyl. 2 is optionally substituted 2-naphthyl. 2 is an aralkyl.

[0200] In another embodiment, the selective HDAC6 inhibitor is a compound having formula V, where X is X-2. In another embodiment, Z is -O-. In another embodiment, Z is -N(R 8 In another embodiment, Z is —C(═O)—. In another embodiment, R 3 is an optionally substituted C-C 14 In another embodiment, R 3 is an optionally substituted 5- to 14-membered heteroaryl. In another embodiment, R 3 is -C(=O)NR d R e In another embodiment, Z is absent and R 3 is a bicyclic or tricyclic C 10-14 Aryl, bicyclic or tricyclic 9-14 membered heteroaryl, or -C(=O)NR d R e is.

[0201] In another embodiment, the selective HDAC6 inhibitor is a compound having formula V, where X is X-3.

[0202] In another embodiment, the selective HDAC6 inhibitor is a compound having formula V, where X is X-4.

[0203] In another embodiment, the selective HDAC6 inhibitor is a compound having formula V, where X is X-5.

[0204] In another embodiment, the selective HDAC6 inhibitor is represented by Formula I: [ka] or a pharmaceutically acceptable salt thereof (In the formula, R 6a , R 6b , R 6c , R 6d , and R 6e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-6 selected from the group consisting of cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, and optionally substituted 5- or 6-membered heterocyclo; R a and R b are independently hydrogen and C 1-4 alkyl; or R a and R btogether with the nitrogen atom to which they are attached form a 3- to 7-membered heterocycle; R c is C 1-4 is alkyl; where n is 1, 2, or 3).

[0205] In another embodiment, the selective HDAC6 inhibitor is a compound having Formula I, wherein R 6a , R 6b , R 6c , R 6d , and R 6e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 In another embodiment, R 6a , R 6b , R 6c , R 6d , and R 6e are each independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 alkoxy is selected from the group consisting of:

[0206] In another embodiment, the selective HDAC6 inhibitor is a compound having Formula I, where n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0207] In another embodiment, the selective HDAC6 inhibitor has Formula II: [ka] or a pharmaceutically acceptable salt thereof (In the formula, R 7a , R 7b , R 7c , R 7d , and R 7eare each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-6 selected from the group consisting of cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, and optionally substituted 5- or 6-membered heterocyclo; R a and R b are independently hydrogen and C 1-4 alkyl; or R a and R b together with the nitrogen atom to which they are attached form a 3- to 7-membered heterocycle; R c is C 1-4 is alkyl; where n is 1, 2, or 3).

[0208] In another embodiment, the selective HDAC6 inhibitor is a compound having Formula II, wherein R 7a , R 7b , R 7c , R 7d , and R 7e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 In another embodiment, R 7a , R 7b , R 7c, R 7d , and R 7e are each independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 alkoxy is selected from the group consisting of:

[0209] In another embodiment, the selective HDAC6 inhibitor is a compound having Formula II, where n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0210] In another embodiment, the selective HDAC6 inhibitor has Formula III: [ka] or a pharmaceutically acceptable salt thereof, wherein R 4a and R 4b are independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 selected from the group consisting of alkoxy; R 4c and R 4d is independently selected from the group consisting of hydrogen and methyl; m is 0 or 1; n is 1, 2, or 3; [ka] represents a single or double bond).

[0211] In another embodiment, the selective HDAC6 inhibitor is a compound having Formula III, wherein m is 0; [ka] represents a double bond).

[0212] In another embodiment, the selective HDAC6 inhibitor is a compound having Formula III, wherein m is 1; [ka] represents a single bond).

[0213] In another embodiment, the selective HDAC6 inhibitor is a compound having Formula III, where n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0214] In another embodiment, the selective HDAC6 inhibitor is represented by Formula IV: [ka] or a pharmaceutically acceptable salt thereof (In the formula, R 5a and R 5c are independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 selected from the group consisting of alkoxy; where n is 1, 2, or 3).

[0215] In another embodiment, the selective HDAC6 inhibitor is a compound having Formula IV, where n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

[0216] In another embodiment, the selective HDAC6 inhibitor is a compound of Table 2 or a pharmaceutically acceptable salt thereof. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] Table 5-7 Table 5-8 Table 5-9 Table 5-10 Table 5-11 Table 5-12 Table 5-13 Table 5-14 Table 5-15 Table 5-16 Table 5-17 Table 5-18 Table 5-19 Table 5-20 Table 5-21 Table 5-22 Table 5-23

[0217] In the present disclosure, the term "macrophage polarization agent," as used herein, refers to an agent that polarizes macrophages. Macrophage polarization is the process by which macrophages adopt different functional programs in response to signals from the microenvironment. Macrophage polarization allows them to impart a variety of heterogeneous functions and phenotypes depending on activation in terms of stimulus duration and spatial localization. Non-limiting examples of macrophage-polarizing agents include, but are not limited to, lipopolysaccharide (LPS), interferon-gamma (IFN-γ), interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-10, interleukin-12, interleukin-13, interleukin-18, interleukin-23, transforming growth factor beta (TGF-β), glucocorticoids, lipoteichoic acid (LTA), granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF), immune complexes (IC), interleukin-1β, adenosine, or combinations thereof. See, e.g., Rubio et al., Clinical and Translational Oncology 21:391-403 (2019).

[0218] In the present disclosure, the term "tumor antigen," as used herein, refers to an antigenic substance produced in tumor cells that can elicit an immune response in the host. Tumor antigens can be divided into two categories: one category is the product of mutated oncogenes and tumor suppressor genes, and the other category is the product of other mutated genes, including overexpressed or aberrantly expressed cellular proteins, tumor antigens produced by oncogenic viruses, carcinoembryonic antigens, modified cell surface glycolipids and glycoproteins, and cell type-specific differentiation antigens. Non-limiting exemplary tumor antigens include, but are not limited to, alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), cancer antigen 15-3 (CA15-3), cancer antigen 19-9 (CA19-9), mucin 1 (MUC-1), epithelial tumor antigen (ETA), tyrosinase, or melanoma-associated antigen (MAGE), B melanoma antigen (BAGE), CAGE, New York esophageal squamous cell carcinoma 1 (NY-ESO-1), melanoma antigen recognized by T cells 1 (MART-1), prostate-specific antigen (PSA), human epidermal growth factor receptor 2 (HER2), calcitonin, and p53. In some embodiments, the one or more tumor antigens comprise alphafetoprotein (AFP), carcinoembryonic antigen (CEA), CA-125, MUC-1, epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), or p53, or a combination thereof.

[0219] In this disclosure, the term "halo" or "halogen," when used by itself or as part of another group, refers to -Cl, -F, -Br, or -I. In one aspect, halo is -Cl or -F. In one aspect, halo is -Cl.

[0220] In this disclosure, the term "nitro" used by itself or as part of another group refers to -NO2.

[0221] In this disclosure, the term "cyano" used by itself or as part of another group refers to --CN.

[0222] For purposes of this disclosure, the term "hydroxy" when used by itself or as part of another group refers to --OH.

[0223] In this disclosure, the term "alkyl" when used by itself or as part of another group refers to alkyl groups containing 1 to 12 carbon atoms, i.e., C 1-12 Alkyl, or a group having a specified number of carbon atoms, e.g., C1 alkyl such as methyl, C2 alkyl such as ethyl, C3 alkyl such as propyl or isopropyl, C4 alkyl such as methyl, ethyl, propyl, or isopropyl. 1-3 alkyl refers to an unsubstituted straight or branched chain aliphatic hydrocarbon, including C1- 10 In another aspect, alkyl is C 1-6 In another aspect, alkyl is C 1-4 In another embodiment, the alkyl is a straight chain C 1-10 In another embodiment, the alkyl is a branched C 3-10 In another embodiment, the alkyl is a straight chain C 1-6 In another embodiment, the alkyl is a branched C 3-6 In another embodiment, the alkyl is a straight chain C 1-4 In another embodiment, the alkyl is a branched C 3-4 In another embodiment, the alkyl is a straight or branched chain C 3-4 Non-limiting exemplary C 1-10 Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, iso-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, and decyl. 1-4 Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, and iso-butyl.

[0224] In this disclosure, the term "cycloalkyl" when used by itself or as part of another group refers to a group having 3 to 12 carbon atoms, i.e., C 3-12 Cycloalkyl refers to saturated and partially unsaturated (containing one or two double bonds) cyclic aliphatic hydrocarbons containing one to three rings having the specified number of carbons. In one aspect, a cycloalkyl group has two rings. In one aspect, a cycloalkyl group has one ring. In another aspect, a cycloalkyl group has C 3-8 In another aspect, the cycloalkyl group is selected from C 3-6 Non-limiting exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, cyclopentenyl, and cyclohexenyl.

[0225] In this disclosure, the term "optionally substituted cycloalkyl" used by itself or as part of another group means that cycloalkyl as defined above is unsubstituted or substituted with halogen, hydroxy, nitro, cyano, -SCH, -SCF, -NR a R b , -C(O)NR a R b , -C(=O)CH3, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, optionally substituted C 3-8 "Cycloalkyl" means substituted with 1, 2, or 3 substituents independently selected from the group consisting of cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclo. In one aspect, the optionally substituted cycloalkyl is substituted with 2 substituents. In another aspect, the optionally substituted cycloalkyl is substituted with 1 substituent.

[0226] In this disclosure, the term "alkenyl," used by itself or as part of another group, refers to an alkyl group as defined above containing one, two, or three carbon-carbon double bonds. In one aspect, an alkenyl group is 2-6 In another aspect, the alkenyl group is selected from C 2-4 Alkenyl groups are selected from the group consisting of: ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.

[0227] In this disclosure, the term "alkynyl," used by itself or as part of another group, refers to an alkyl group, as defined above, containing one to three carbon-carbon triple bonds. In one aspect, an alkynyl group has one carbon-carbon triple bond. In one aspect, an alkynyl group has a C 2-6 In another aspect, the alkynyl group is selected from C 2-4 alkynyl groups. Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.

[0228] In the present disclosure, the term "haloalkyl," when used by itself or as part of another group, refers to an alkyl group substituted with one or more fluorine, chlorine, bromine, and / or iodine atoms. In one aspect, the alkyl group is substituted with 1, 2, or 3 fluorine and / or chlorine atoms. In another aspect, a haloalkyl group is a C 1-6 In another aspect, the haloalkyl group is C 1-4 Haloalkyl groups. Non-limiting exemplary haloalkyl groups include fluoromethyl, 2-fluoroethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups.

[0229] In this disclosure, the term "alkoxy," when used by itself or as part of another group, refers to an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, or optionally substituted alkynyl attached to a terminal oxygen atom. In one aspect, an alkoxy group is a C 1ー4 In another aspect, the alkoxy group is selected from C 1-6 In another embodiment, the alkoxy group is selected from a C bonded to a terminal oxygen atom. 1-4 Alkyl is selected from, for example, methoxy, ethoxy, and tert-butoxy.

[0230] In this disclosure, the term "haloalkoxy" when used by itself or as part of another group refers to a C bonded to a terminal oxygen atom. 1-4 refers to haloalkyl. Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy.

[0231] In this disclosure, the term "aryl," when used by itself or as part of another group, refers to a monocyclic, bicyclic, or tricyclic aromatic ring system having 6 to 14 carbon atoms (i.e., C6-C 14 aryl). Non-limiting exemplary aryl groups include phenyl (abbreviated as "Ph"), 1-naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl. In one aspect, the aryl group is selected from phenyl, 1-naphthyl, or 2-naphthyl. In one aspect, aryl is a bicyclic or tricyclic C 10 -C 14 It is an aromatic ring system.

[0232] In the present disclosure, the term "optionally substituted aryl" as used herein by itself or as part of another group refers to aryl as defined above, which is unsubstituted or substituted with halogen, hydroxy, nitro, cyano, -SCH, -SCF, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-12 Cycloalkyl, optionally substituted C-C 14 means that the group is substituted with 1 to 5 substituents independently selected from the group consisting of aryl, optionally substituted 5- to 14-membered heteroaryl, and optionally substituted 3- to 14-membered heterocyclo; a and R b are independently hydrogen and C 1-6 alkyl; or R a and R b together with the nitrogen atom to which they are attached form a 3- to 12-membered heterocycle; R c is C 1-4 It is alkyl.

[0233] In one embodiment, the optionally substituted aryl is an optionally substituted phenyl. In one embodiment, the optionally substituted phenyl has four substituents. In another embodiment, the optionally substituted phenyl has three substituents. In another embodiment, the optionally substituted phenyl has two substituents. In another embodiment, the optionally substituted phenyl has one substituent. Non-limiting exemplary substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-difluorophenyl, 3,4-dichlorophenyl, 3,5-dimethylphenyl, 3,5-dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, and 3-chloro-4-fluorophenyl. The term optionally substituted aryl is meant to include groups having optionally substituted fused cycloalkyl and optionally substituted fused heterocyclic rings. Non-limiting examples include: [ka] Examples include:

[0234] In this disclosure, the term "heteroaryl" refers to monocyclic, bicyclic, and tricyclic aromatic ring systems having 5 to 14 ring atoms, i.e., 5- to 14-membered heteroaryls, wherein at least one carbon atom of one of the rings is independently replaced with a heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur. In one aspect, a heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. In one aspect, a heteroaryl has 3 heteroatoms. In another aspect, a heteroaryl has 2 heteroatoms. In another aspect, a heteroaryl has 1 heteroatom. Non-limiting exemplary heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzoxazonyl, chromenyl, xanthenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, Examples include indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, and phenoxazinyl.In one aspect, heteroaryl is thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., 1H-pyrrol-2-yl and 1H-pyrrol-3-yl), imidazolyl (e.g., 2H-imidazol-2-yl and 2H-imidazol-4-yl), pyrazolyl (e.g., 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, and 1H-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrrolyl (e.g., pyrimidin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrrolyl (e.g., pyrimidin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrrolyl (e.g., pyrimidin-2-yl, pyridin-4-yl), pyrrolyl (e.g., pyrimidin-5-yl, pyridin-5 ... The heteroaryl group is selected from the group consisting of pyrimidin-4-yl and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl), and isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl), and indazolyl (e.g., 1H-indazol-3-yl). The term "heteroaryl" is also intended to include possible N-oxides. A non-limiting exemplary N-oxide is pyridyl N-oxide.

[0235] In one embodiment, the heteroaryl is a 5- or 6-membered heteroaryl. In one embodiment, the heteroaryl is a 5-membered heteroaryl. That is, the heteroaryl is a monocyclic aromatic ring system having 5 ring atoms, in which at least one carbon atom of the ring is replaced with a heteroatom independently selected from nitrogen, oxygen, and sulfur. Non-limiting exemplary 5-membered heteroaryl groups include thienyl, furyl, pyrrolyl, oxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, and isoxazolyl.

[0236] In another embodiment, the heteroaryl is a 6-membered heteroaryl, e.g., the heteroaryl is a monocyclic aromatic ring system having 6 ring atoms in which at least one carbon atom of the ring is replaced with a nitrogen atom. Non-limiting exemplary 6-membered heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl.

[0237] In another embodiment, the heteroaryl is a 9- to 14-membered bicyclic aromatic ring system in which at least one carbon atom of one of the rings is replaced with a heteroatom independently selected from the group consisting of oxygen, nitrogen, and sulfur. Non-limiting exemplary 9- to 14-membered bicyclic aromatic ring systems include: [ka]

[0238] In the present disclosure, the term "optionally substituted heteroaryl" used by itself or as part of another group refers to heteroaryl as defined above, which is unsubstituted or substituted with halogen, hydroxy, nitro, cyano, -SCH, -SCF, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-12 Cycloalkyl, optionally substituted C-C 14 means that the group is substituted with 1 to 4 substituents independently selected from the group consisting of aryl, optionally substituted 5- to 14-membered heteroaryl, and optionally substituted 3- to 14-membered heterocyclo; a and R b are independently hydrogen and C 1-6 alkyl; or R aand R b together with the nitrogen atom to which they are attached form a 3- to 12-membered heterocycle; R c is C 1-4 In one embodiment, an optionally substituted heteroaryl has one substituent. Any available carbon or nitrogen atom can be substituted.

[0239] In this disclosure, the terms "heterocycle" or "heterocyclo," when used by itself or as part of another group, refer to saturated and partially unsaturated (e.g., containing one or two double bonds) cyclic groups containing one, two, or three rings having 3 to 14 ring members (i.e., 3- to 14-membered heterocyclos) and at least one heteroatom, where at least one carbon atom of one of the rings is replaced with a heteroatom. Each heteroatom is independently selected from the group consisting of oxygen, sulfur, e.g., sulfoxide and sulfone, and / or nitrogen atoms, which may be oxidized or quaternized. The term "heterocyclo" is meant to include groups in which the ring -CH- is replaced with -C(=O)-, e.g., cyclic ureido groups such as 2-imidazolidinone, and cyclic amide groups such as β-lactam, γ-lactam, δ-lactam, ε-lactam, and piperazin-2-one. The term "heterocyclo" is also meant to include groups having optionally substituted fused aryl groups, such as indolinyl. In one aspect, heterocyclo groups are selected from 5- or 6-membered ring groups containing one ring and one or two oxygen and / or nitrogen atoms. The heterocyclo can be optionally linked to the remainder of the molecule through any available carbon or nitrogen atom. Non-limiting exemplary heterocyclo groups include dioxanyl, tetrahydropyranyl, 2-oxopyrrolidin-3-yl, piperazin-2-one, piperazine-2,6-dione, 2-imidazolidinone, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, and indolinyl.

[0240] In the present disclosure, the term "optionally substituted heterocyclo" as used herein by itself or as part of another group refers to heterocyclo as defined above, which is unsubstituted or substituted with halogen, hydroxy, nitro, cyano, -SCH, -SCF, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-12 Cycloalkyl, optionally substituted C-C 14 means that the group is substituted with 1 to 4 substituents independently selected from the group consisting of aryl, optionally substituted 5- to 14-membered heteroaryl, and optionally substituted 3- to 14-membered heterocyclo; a and R b are independently hydrogen and C 1-6 alkyl; or R a and R b together with the nitrogen atom to which they are attached form a 3- to 12-membered heterocycle; R c is C 1-4 It is alkyl.

[0241] In this disclosure, the term "aralkyl," when used by itself or as part of another group, refers to an alkyl group substituted with one, two, or three optionally substituted aryl groups. In one aspect, an optionally substituted aralkyl group is a C substituted with one optionally substituted aryl group. 1-4In one aspect, the aralkyl group is a C1 or C2 alkyl substituted with one optionally substituted aryl group. In one aspect, the aralkyl group is a C1 or C2 alkyl substituted with one optionally substituted phenyl group. Non-limiting exemplary aralkyl groups include benzyl, phenethyl, -CHPh2, -CH2(4-F-Ph), -CH2(4-Me-Ph), -CH2(4-CF3-Ph), and -CH(4-F-Ph)2.

[0242] In this disclosure, the term "heteroaralkyl," when used by itself or as part of another group, refers to an alkyl group substituted with one, two, or three optionally substituted heteroaryl groups. In one aspect, a heteroaralkyl group is a C substituted with one optionally substituted heteroaryl group. 1-4 In one aspect, the aralkyl group is a C1 or C2 alkyl substituted with one optionally substituted heteroaryl group. In one aspect, the heteroaralkyl group is a C1 or C2 alkyl substituted with one optionally substituted heteroaryl group. Non-limiting exemplary heteroaralkyls include: [ka]

[0243] The term "HDAC" refers to a family of enzymes that remove acetyl groups from proteins, for example, the epsilon amino group of lysine residues at the N-terminus of histones. HDACs can be any human HDAC isoform, such as HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, and HDAC11. HDACs can also be obtained from protozoan or fungal sources.

[0244] As used herein, the terms "treat," "treating," "treatment," and the like refer to eliminating, reducing, alleviating, reversing, and / or ameliorating a disorder and / or condition and / or its associated symptoms. Treating a disease or condition does not require complete elimination of the disease, condition, or its associated symptoms, such as treating acute or chronic signs, symptoms, and / or dysfunctions. As used herein, the terms "treat," "treating," "treatment," and the like may include "prophylactic treatment," which refers to reducing the likelihood of a disease or condition recurring or the likelihood of a previously controlled disease or condition recurring in a subject who has not experienced a recurrence of the disease or condition but is at risk of or susceptible to a recurrence of the disease or condition. Thus, "treatment" also includes recurrence prevention or phase prevention. The term "treat" and cognate terms contemplate administering a therapeutically effective amount of a compound of the present disclosure to an individual in need of such treatment, e.g., a mammalian patient, including, but not limited to, a human or veterinary animal. Treatment may be symptomatic, e.g., to suppress symptoms. This can be short term, adaptive in the medium term, or may be long term treatment, for example in the context of maintenance therapy.

[0245] As used herein, the term "therapeutically effective amount" or "therapeutic dose" refers to an amount of an active ingredient that, when administered, is sufficient to effectively deliver the active ingredient(s) to an individual in need thereof, e.g., a human patient, for the treatment of a desired condition or disease. In the case of cancer or other proliferative disorders, a therapeutically effective amount of an agent can reduce (i.e., slow to some extent, and preferably stop) unwanted cell proliferation; reduce the number of cancer cells; shrink tumor size; inhibit (i.e., slow to some extent, and preferably stop) cancer cell invasion into peripheral organs; inhibit (i.e., slow to some extent, and preferably stop) tumor metastasis; inhibit tumor growth to some extent; reduce HDAC signaling in target cells; and / or alleviate to some extent one or more symptoms associated with cancer. To the extent that the administered compound or composition prevents growth and / or kills existing cancer cells, it can be cytostatic and / or cytotoxic.

[0246] The use of the terms "a," "an," "the," and similar referents in the context of describing the disclosure (particularly in the context of the claims) should be construed to cover both the singular and the plural unless otherwise indicated. The recitation of ranges of values ​​herein merely serves as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value and subrange is incorporated herein as if individually recited herein. The use of any and all examples or exemplary language (e.g., "such as" and "like") provided herein is intended to better illustrate the disclosure and does not limit the scope of the disclosure unless otherwise asserted. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.

[0247] As used herein, the term "about" includes the recited number plus or minus 10%. Thus, "about 10" means 9 to 11.

[0248] As used herein, the term "subject" refers to any human or mammal in need of or that may benefit from treatment with STAT-activated macrophages. Foremost among such subjects are humans, although the methods and compositions provided herein are not intended to be so limited. Other subjects include veterinary animals, such as cows, sheep, pigs, horses, dogs, cats, and the like. In one embodiment, the subject is a human. In certain embodiments, the subject is a mammal.

[0249] The selective HDAC6 inhibitor can exist as a salt.As used herein, the term "pharmaceutically acceptable salt" refers to the salt or zwitterionic form of the compound.The salt of the compound can be prepared during the final isolation and purification of the compound, or separately by reacting the compound with an acid having a suitable cation.The pharmaceutically acceptable salt of the compound can be an acid addition salt formed with a pharmaceutically acceptable acid.Examples of acids that can be used to form pharmaceutically acceptable salts include inorganic acids such as nitric acid, boric acid, hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, and organic acids such as oxalic acid, maleic acid, succinic acid, tartaric acid, and citric acid. Non-limiting examples of salts of selective HDAC6 inhibitors include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, sulfate, hydrogen sulfate, 2-hydroxyethanesulfonate, phosphate, hydrogen phosphate, acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerol phosphate, hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate, maleate, ascorbate, isethionate, salicylate, methanesulfonate, Examples of suitable salts include phosphate, mesitylenesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, paratoluenesulfonate, undecanoate, lactate, citrate, tartrate, gluconate, methanesulfonate, ethanedisulfonate, benzenesulfonate, and p-toluenesulfonate salts. Additionally, available amino groups present in the selective HDAC6 inhibitors may be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.Any reference to a compound of the present disclosure appearing herein is intended to include the selective HDAC6 inhibitors, as well as pharmaceutically acceptable salts, solvates, or hydrates thereof. [Example]

[0250] General method Bone marrow-derived macrophages (BMDM): Macrophages were isolated from bone marrow of 6-12 week-old C57BL / 6 mice according to an IACUC-approved protocol. Briefly, femurs and tibias were isolated after removing skeletal muscle. The bone marrow was flushed with RPMI complete medium supplemented with non-essential amino acids. A single-cell suspension of bone marrow was prepared by repeated pipetting and then incubated with 20 ng / mL mouse recombinant M-CSF (Biolegend) at 37°C for 4 days to differentiate into macrophages.

[0251] Flow cytometry: Flow cytometry was performed according to a previously described protocol. Knox et al., Sci Rep. 2019 Oct 10;9(1):14824. doi:10.1038 / s41598-019-51403-6. Briefly, mice were euthanized according to IACUC protocol, and tumor cells were processed into a single-cell suspension for analysis by flow cytometry using tumor digestion buffer. The following antibodies were used to stain cell surface markers expressed by different immune cells. Unless otherwise noted, all antibodies were purchased from Biolegend (San Diego, CA). Myeloid cell surface markers were as follows: APC anti-mouse CD80 (clone 16-10A1), PE / Cy7 anti-mouse CD206 (MMR) (clone C068C2), APC / Fire™ 750 anti-mouse CD45.2 (clone 104), FITC anti-mouse H-2 (clone M1 / 42), BrilliantViolet785™ anti-mouse F4 / 80 (clone BM8), and AlexaFluor® 700 anti-mouse CD3 (clone 17A2). To distinguish MHCI from MHCI bound to SIINFEKL, APC anti-mouse H-2Kb (clone 25-D1.16) conjugated to SIINFEKL antibody was used. Multicolor flow data acquisition was performed on a BD Celesta, and data analysis was performed with FlowJo software (version 10.3). Statistical analysis was performed using GraphPad Prism (version 7.03) software.

[0252] Example 1 Pretreatment of BMDMs with a STAT3 inhibitor reduces M2 polarization Bone marrow-derived macrophages (BMDMs) were differentiated into macrophages with M-CSF. These naive macrophages were pretreated with nextulastat A (NextA) or 6-nitrobenzo[b]thiophene-1,1-dioxide (Stattic) and polarized to M2 macrophages with IL-4 / IL-13. As shown by flow cytometry, pretreatment with NextA and Stattic reduced M2 macrophage polarization. See Figure 1.

[0253] Further validation of M2 polarization markers at the gene expression level by quantitative real-time PCR showed that tumor-promoting factors arginase I, TGFβ, and FIZZ1 were reduced (Figures 2, 3, and 4). These data suggest that pretreatment with NextA and Stattic affects cell signaling and programming of naive macrophages in response to polarizing factors in the tumor microenvironment (TME).

[0254] All of the features described in this specification (including any accompanying claims, abstract and drawings), and / or all of the steps of any disclosed method, may be combined with any of the above aspects in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive.

[0255] It is to be understood that the foregoing aspects and examples are not intended to limit the scope of the present disclosure in any way, and that the claims presented herein are intended to encompass all aspects, embodiments, and examples, whether or not expressly presented herein.

[0256] All patents, patent applications, and publications cited herein are hereby incorporated by reference in their entirety.

Claims

1. Signal transducer and activator of transcription (STAT)-activated macrophages.

2. A composition comprising the STAT-activated macrophage of claim 1.

3. 3. The composition of claim 2, wherein the STAT-activated macrophages are generated from naive macrophages that have been isolated from a subject and treated ex vivo with a STAT inhibitor.

4. The composition of claim 3 , wherein the subject is a mammal.

5. The composition of claim 4 , wherein the subject is a human.

6. The composition according to any one of claims 3 to 5, wherein the naive macrophages are allogeneic macrophages, autologous macrophages, or a combination of allogeneic and autologous macrophages.

7. The composition of claim 6 , wherein the naive macrophages are autologous macrophages.

8. The composition of any one of claims 3 to 7, wherein the ex vivo treatment of the isolated naive macrophages comprises a single treatment with the STAT inhibitor.

9. The composition of any one of claims 3 to 7, wherein the ex vivo treatment of the isolated naive macrophages comprises two or more treatments with the STAT inhibitor.

10. The composition of any one of claims 3 to 9, wherein the ex vivo treatment of the isolated naive macrophages further comprises treatment with one or more macrophage polarizing agents.

11. 11. The composition of claim 10, wherein the macrophage polarizing agent comprises lipopolysaccharide (LPS), interferon-γ, interleukin-4, or interleukin-13, or a combination thereof.

12. The composition of any one of claims 3 to 11, wherein the ex vivo treatment of the naive macrophages further comprises treatment with one or more tumor antigens.

13. 13. The composition of claim 12, wherein the one or more tumor antigens comprise alphafetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), cancer antigen 15-3 (CA15-3), cancer antigen 19-9 (CA19-9), mucin 1 (MUC-1), epithelial tumor antigen (ETA), tyrosinase, or melanoma associated antigen (MAGE), B melanoma antigen (BAGE), CAGE, New York esophageal squamous cell carcinoma 1 (NY-ESO-1), melanoma antigen recognized by T cells 1 (MART-1), prostate specific antigen (PSA), human epidermal growth factor receptor 2 (HER2), calcitonin, or p53, or a combination thereof.

14. The composition of any one of claims 3 to 13, wherein the ex vivo treatment of the naive macrophages further comprises treatment with one or more selective HDAC6 inhibitors.

15. The selective HDAC6 inhibitor has formula I: [Formula 1] or a pharma- ceutically acceptable salt thereof. (In the formula, R 6a , R 6b , R 6c , R 6d , and R 6e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-6 selected from the group consisting of cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, and optionally substituted 5- or 6-membered heterocyclo; R a and R b are independently hydrogen and C 1-4 alkyl; or R a and R b together with the nitrogen atom to which they are attached form a 3- to 10-membered heterocycle; R c is C 1-4 is alkyl; n is 1, 2, or 3).

16. The selective HDAC6 inhibitor has formula II: [chemical 2] or a pharma- ceutically acceptable salt thereof. (In the formula, R 7a , R 7b , R 7c , R 7d , and R 7e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-6selected from the group consisting of cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, and optionally substituted 5- or 6-membered heterocyclo; R a and R b are independently hydrogen and C 1-4 alkyl; or R a and R b together with the nitrogen atom to which they are attached form a 3- to 10-membered heterocycle; R c is C 1-4 is alkyl; n is 1, 2, or 3).

17. The selective HDAC6 inhibitor has formula III: [C3] or a pharma- ceutically acceptable salt thereof, R 4a and R 4b are independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 alkoxy; R 4c and R 4d is independently selected from the group consisting of hydrogen and methyl; m is 0 or 1; n is 1, 2, or 3; [C4] represents a single or double bond).

18. The selective HDAC6 inhibitor has formula IV: [C5] or a pharma- ceutically acceptable salt thereof, R 5a and R 5c are independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 alkoxy; n is 1, 2, or 3).

19. 15. The composition of claim 14, wherein the selective HDAC6 inhibitor is a compound of Table 2 or a pharma- ceutically acceptable salt thereof.

20. The composition of any one of claims 14 to 19, wherein the selective HDAC6 inhibitor is at least about 20-fold more selective than one or more other HDAC isoforms.

21. The composition of any one of claims 3 to 20, wherein the STAT inhibitor is a STAT3 inhibitor.

22. 22. The composition of claim 21, wherein the STAT3 inhibitor is 6-nitrobenzo[b]thiophene-1,1-dioxide.

23. 1. A method of producing STAT-activated macrophages, comprising treating naive macrophages ex vivo with a STAT inhibitor, wherein the naive macrophages are isolated from a subject.

24. 24. The method of claim 23, wherein the subject is a mammal.

25. 25. The method of claim 24, wherein the subject is a human.

26. The method of any one of claims 23 to 25, wherein the naive macrophages are allogeneic macrophages, autologous macrophages, or a combination of allogeneic and autologous macrophages.

27. 27. The method of claim 26, wherein the naive macrophages are autologous macrophages.

28. The method of any one of claims 23 to 27, wherein the ex vivo treatment of the naive macrophages comprises a single treatment with the STAT inhibitor.

29. The method of any one of claims 23 to 27, wherein the ex vivo treatment of the naive macrophages comprises two or more treatments with the STAT inhibitor.

30. 30. The method of any one of claims 23 to 29, wherein the ex vivo treatment of the naive macrophages further comprises treatment with one or more macrophage polarizing agents.

31. 31. The method of claim 30, wherein the macrophage polarizing agent comprises lipopolysaccharide (LPS), interferon-gamma, interleukin-4, or interleukin-13, or a combination thereof.

32. The method of any one of claims 23 to 31, wherein the ex vivo treatment of the naive macrophages further comprises treatment with one or more tumor antigens.

33. 33. The method of claim 32, wherein the one or more tumor antigens comprise alphafetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), cancer antigen 15-3 (CA15-3), cancer antigen 19-9 (CA19-9), mucin 1 (MUC-1), epithelial tumor antigen (ETA), tyrosinase, or melanoma associated antigen (MAGE), B melanoma antigen (BAGE), CAGE, New York esophageal squamous cell carcinoma 1 (NY-ESO-1), melanoma antigen recognized by T cells 1 (MART-1), prostate specific antigen (PSA), human epidermal growth factor receptor 2 (HER2), calcitonin, or p53, or a combination thereof.

34. The method of any one of claims 23 to 33, wherein the ex vivo treatment of the naive macrophages further comprises treatment with one or more selective HDAC6 inhibitors.

35. The selective HDAC6 inhibitor has formula I: [C6] or a pharma- ceutically acceptable salt thereof, R 6a , R 6b , R 6c , R 6d , and R 6e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-6 selected from the group consisting of cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, and optionally substituted 5- or 6-membered heterocyclo; R a and R b are independently hydrogen and C 1-4 alkyl; or R a and R b together with the nitrogen atom to which they are attached form a 3- to 10-membered heterocycle; R c is C 1-4 is alkyl; n is 1, 2, or 3).

36. The selective HDAC6 inhibitor has formula II: [C7] or a pharma- ceutically acceptable salt thereof, R 7a , R 7b , R 7c , R 7d , and R 7e are each independently hydrogen, halogen, hydroxy, nitro, cyano, -NR a R b , -C(=O)NR a R b , -C(=O)R c , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, haloalkoxy, optionally substituted C 3-6 selected from the group consisting of cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, and optionally substituted 5- or 6-membered heterocyclo; R a and R b are independently hydrogen and C 1-4 alkyl; or R a and R b together with the nitrogen atom to which they are attached form a 3- to 10-membered heterocycle; R c is C 1-4 is alkyl; n is 1, 2, or 3).

37. The selective HDAC6 inhibitor has formula III: [C8] or a pharma- ceutically acceptable salt thereof. (In the formula, R 4a and R 4b are independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 alkoxy; R 4c and R 4d is independently selected from the group consisting of hydrogen and methyl; m is 0 or 1; n is 1, 2, or 3; [C9] represents a single or double bond).

38. The selective HDAC6 inhibitor has formula IV: [C10] or a pharma- ceutically acceptable salt thereof. (In the formula, R 5a and R 5c are independently hydrogen, halogen, cyano, C 1-4 Alkyl, and C 1-4 alkoxy; n is 1, 2, or 3).

39. 35. The method of claim 34, wherein the selective HDAC6 inhibitor is a compound of Table 2 or a pharma- ceutically acceptable salt thereof.

40. 40. The method of any one of claims 34 to 39, wherein the selective HDAC6 inhibitor inhibits HDAC6 at least 20 times more than it inhibits one or more of HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, HDAC10, or HDAC11.

41. The method of any one of claims 23 to 40, wherein the STAT inhibitor is a STAT3 inhibitor.

42. 42. The method of claim 41, wherein the STAT3 inhibitor is 6-nitrobenzo[b]thiophene-1,1-dioxide.

43. STAT-activated macrophages obtained by the method according to any one of claims 23 to 42.

44. 23. The composition of any one of claims 2 to 22 for treating a subject in need thereof, wherein the subject has cancer, pulmonary fibrosis, liver fibrosis, or cardiac fibrosis.

45. 45. The composition of claim 44, wherein the subject has cancer.

46. The composition described in claim 45, characterized in that the composition is administered to the subject in combination with one or more of radiation therapy, immune checkpoint blockade therapy, photothermal therapy, or chemotherapy.

47. 45. The composition of claim 44, wherein the subject has pulmonary fibrosis.

48. The composition of claim 44, wherein the subject has liver fibrosis.

49. 45. The composition of claim 44, wherein the subject has cardiac fibrosis.

50. The composition of any one of claims 44 to 49, wherein the subject is a human.